GlassScriptPhysician profile
Sheri L Chacon
NPI 1497925424
$4,452.40
in general payments reported to CMS, 2019-2025
42 companies · $519 in 2025
The $519 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $942 · 2022: $1,261 · 2023: $1,158 · 2024: $571 · 2025: $519.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,199 · Long Term Medical Supply Or Device Loan: $49.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,198.71 |
| Long Term Medical Supply Or Device Loan | $49.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $929.94 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $530.55 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Teva Pharmaceuticals USA, INC. | $463.29 | 2021-2024 | Austedo Xr, Austedo, Uzedy |
| Abbott Laboratories | $390.16 | 2022-2025 | Proclaim, Freestyle Insulinx, Freestyle Libre 2 |
| Janssen Pharmaceuticals, INC | $274.78 | 2023-2024 | Spravato |
| Novo Nordisk INC | $202.86 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $176.48 | 2022-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $150.09 | 2022 | |
| Ucb, INC. | $132.86 | 2023-2024 | Briviact, Nayzilam |
| Lucid Diagnostics INC. | $110.03 | 2021 | |
| Boston Scientific Corporation | $104.42 | 2021-2023 | Accolade Sr |
| Intuitive Surgical, INC. | $94.10 | 2023 | |
| Novartis Pharmaceuticals Corporation | $73.78 | 2022-2023 | |
| Sk Life Science, INC. | $62.70 | 2024 | |
| Xeris Pharmaceuticals, INC. | $57.13 | 2021-2022 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $49.33 | 2022-2023 | Resolute Onyx |
| Sumitomo Pharma America, INC. | $44.02 | 2023-2024 | Gemtesa |
| Optos, INC. | $43.94 | 2021-2022 | |
| Lilly USA, LLC | $42.00 | 2022-2024 | Mounjaro |
| Smith+Nephew, INC. | $39.90 | 2023 | Grafix Pl |
| Ultragenyx Pharmaceutical INC. | $36.17 | 2021-2022 | |
| Alfasigma USA, INC. | $34.38 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $34.30 | 2023 | |
| Mylan Specialty L.P. | $30.19 | 2021-2023 | Yupelri |
| Biogen, INC. | $29.94 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $24.21 | 2023 | Abilify Mycite |
| Dexcom, INC. | $23.75 | 2021 | |
| Glaxosmithkline, LLC. | $22.25 | 2023 | Trelegy Ellipta |
| Ardelyx, INC. | $21.64 | 2024 | Ibsrela |
| Globus Medical, INC. | $21.35 | 2025 | Omnia |
| Inspire Medical Systems, INC. | $20.39 | 2024 | Inspire |
| Pfizer INC. | $19.95 | 2024 | |
| Bardy Diagnostics, INC. | $19.76 | 2022 | |
| Hologic Sales and Service, LLC | $19.14 | 2023 | Aptima |
| Nevro Corp. | $18.64 | 2021 | |
| Lundbeck LLC | $17.19 | 2023 | Rexulti |
| Neurelis, INC. | $15.04 | 2022 | |
| Organogenesis INC. | $15.04 | 2021 | |
| Scilex Pharmaceuticals INC. | $15.03 | 2023 | Ztlido |
| Phadia US INC. | $14.50 | 2022 | |
| Paratek Pharmaceuticals, INC. | $14.13 | 2023 | Nuzyra |
| Neurocrine Biosciences, INC. | $13.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheri Chacon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.